EASTERN COOPERATIVE ONCOLOGY GROUP

东方肿瘤合作组

• 批准号: 6513481
• 负责人: Michael Benjamin Atkins
• 金额: $ 15.26万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-05-12 至 2004-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6513481
• 关键词: AIDS; antineoplastics; biological response modifiers; bone marrow transplantation; brain neoplasms; breast neoplasms; cancer prevention; clinical research; clinical trials; combination cancer therapy; combination chemotherapy; cooperative study; fluorescent in situ hybridization; gastrointestinal neoplasms; gene therapy; head /neck neoplasm; health behavior; human subject; human therapy evaluation; leukemia; lymphoma; melanoma; minimal residual disease; multiple myeloma; neoplasm /cancer chemotherapy; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer pharmacology; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neoplasm /cancer vaccine; nucleic acid sequence; pathology; prognosis; reproductive system neoplasm; thorax neoplasm; tissue resource /registry; urinary tract neoplasms

Beth Israel Deaconess Medical Center (BIDMC) resulted from the 1996 merger of the Beth Israel and New England Deaconess Hospitals, two neighbors and major Harvard Medical School institutions in the Longwood Medical Area. The BIDMC faculty, together with newly recruited long-time Boston-based ECOG members now includes an exceptional group of committed clinical cancer researchers. Serving as the principal tertiary/academic resources of the CareGroup Network, BIDMC has a natural and ready-made ECOG network to add to its long tradition of excellence in cancer care as well as both clinical and basic science research. BIDMC is home to nationally recognized centers of special expertise including the Joint Center for Radiation (JCRT), liver and other solid-organ transplantation, AIDS and related malignancies, breast cancer/women's health, malignant melanoma, medical informatics and clinical trials methodology, cytokine and biologic therapy. The Harvard Institute of Medicine (H.I.M.) Located nearby provides outstanding research scientists and laboratory-based components for cooperative group translational research. BIDMC joined ECOG as an affiliate of Vanderbilt University in May 1997. From May '97-October '97, as an affiliate, BIDMC entered 36 cases. Based on this strong activity and a fully satisfactory site visit in September '97, BIDMC was granted Main Member Institution status in October '97 and approved to apply for an ECOG Core Grant in January 1998. From October '97 to December '97, as a main institution, BIDMC enrolled 19 patients to ECOG studies. To date, in 1998 BIDMC has accrued 33 patients, making the total accrual for May '97 to May '98 equal to 88 patients. We are committed to conducting laboratory and clinical research in the ECOG specified areas of cancer prevention, diagnosis, and treatment and have demonstrated high levels of patient accrual in the past and have the potential for even greater contributions, group science, and patient enrollment in the future.

贝丝以色列女执事医疗中心（BIDMC）是由1996年贝丝以色列和新英格兰女执事医院合并，朗伍德医疗区的两家邻居和哈佛医学院的主要机构。 BIDMC的教职员工与新招募的基于波士顿的长期ECOG成员现在包括一群杰出的临床癌症研究人员。 BIDMC是CareGroup网络的主要高等教育/学术资源，具有自然而现成的ECOG网络，可增加其在癌症护理以及临床和基础科学研究方面的悠久传统。 BIDMC是全国认可的特殊专业知识中心的所在地和生物疗法。 位于附近的哈佛医学研究所（H.I.M.）为合作组织翻译研究提供了杰出的研究科学家和基于实验室的组件。 BIDMC于1997年5月加入ECOG担任范德比尔特大学的会员。从97年5月至97年10月，BIDMC进入了36个案件。 基于这项强大的活动和97年9月的完全令人满意的现场访问，BIDMC于97年10月获得了主要会员机构地位，并批准于1998年1月申请ECOG Core Grant。 BIDMC是一个主要机构，将19名患者招募了ECOG研究。 迄今为止，1998年，BIDMC累积了33例患者，使97年5月至98年5月的总应计等于88例患者。我们致力于在ECOG中进行实验室和临床研究指定的预防癌症，诊断和治疗领域，并证明了过去的高水平患者应计，并有可能在贡献更大的贡献，群体科学和患者入学率。未来。